Postmarketing Adverse Drug Experience (PADE) Inspections – Part II
01/09/2025 No Comments
Postmarketing Adverse Drug Experience (PADE) Inspections – Part II Legal Framework of PADE Inspections LAW: Federal Food, Drug and Cosmetic Act (FDCA) Title 21 of ...
Read More → Postmarketing Adverse Drug Experience (PADE) Inspections – Part I
12/02/2024 No Comments
Postmarketing Adverse Drug Experience (PADE) Inspections – Part I Legal Framework of PADE Inspections LAW: Federal Food, Drug and Cosmetic Act (FDCA) Title 21 of ...
Read More → Hy’s law & Drug Induced Liver Injury – Part II
11/22/2024 No Comments
Drug-Induced Liver Injury Occurrence Most frequent cause of acute liver failure in North America and Europe. No definite causative agent has been attributed in several ...
Read More → Hy’s law & Drug Induced Liver Injury – Part I
11/21/2024 No Comments
Drug-Induced Liver Injury Occurrence Most frequent cause of acute liver failure in North America and Europe. No definite causative agent has been attributed in several ...
Read More → Automation Solution – UNITYdx
11/11/2024 No Comments
Essential Automation Solution Components Technology Digital Monitoring of Safety Communications with site Tracking of Delivery Receipts and Acknowledgement Compliance Custom Configurations for Site Reminders and ...
Read More → Transforming Clinical Trial Safety: Regulatory Expectations & Inspection Findings for Site Notifications for SUSARs
11/11/2024 No Comments
US-FDA United States Food and Drug Administration The sponsor must notify all participating investigators (i.e., all investigators to whom the sponsor is providing drug under ...
Read More → REMS Compliance & Inspection
10/01/2024 No Comments
REMS are Enforceable under Section 505-1 REMS must be fully operational before drug introduced into interstate commerce. Drug is deemed to be misbranded (Section 502(y)) ...
Read More → Navigating REMS Audits Inspections – Dr Sumit Verma
10/01/2024 No Comments
What is REMS? Per the USFDA, REMS is defined as:“A required risk management plan that uses risk minimization strategies beyond professional labeling to ensure that ...
Read More → Signal Detection in Early Phase Clinical Drug Trials
10/01/2024 No Comments
Why Should You Perform Signal Detection in Early Phase Clinical Drug Trials? The term ‘pharmacovigilance’ has conventionally been related with post-marketingactivities; however, it is also ...
Read More → Medication Errors Why is it Important to Record, Assess, and Prevent Them
02/22/2024 No Comments
Medication errors are an important concern in healthcare systems around the world. They can occur at any stage of the medication process, from prescribing to ...
Read More → Why you Should Incorporate Signal Detection Process in Early Phase Clinical Development Programs
01/22/2024 No Comments
What is a Safety Signal in Pharmacovigilance? Information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, ...
Read More → Navigating the Unique Challenges of AI and Automation in Pharmacovigilance: The Vital Role of Computer System Validation (CSV)
12/07/2023 No Comments
Artificial Intelligence, Machine Learning, Automation, Cost Reduction: all the buzzwords in pharmacovigilance! Everyone seems to be implementing Automation and AI in pharmacovigilance to reduce manual ...
Read More → Overview of Regulatory Requirement for Post-Marketing Medical Device Reporting in the USA and the EU
11/14/2023 No Comments
Meteriovigilance is the term used in the context of surveillance of medical devices and its purpose is to improve the health and safety of patients, ...
Read More → Audits in Pharmacovigilance: A Commitment to Safety
10/31/2023 No Comments
In the realm of healthcare, ensuring patient safety is the most important aspect. That’s where pharmacovigilance plays a role in safeguarding lives by monitoring the ...
Read More → Causality Assessment in Pharmacovigilance
10/25/2023 No Comments
An adverse drug reaction is distinguished from an adverse event by the fact that in an adverse drug reaction, a causal relationship is suspected between ...
Read More → Pharmacovigilance for Decentralized Clinical Trials
08/08/2023 No Comments
Decentralised clinical trials make clinical trials easier for patients by reducing the need to travel to clinical sites. They are also known as “Direct-to-participant trials” ...
Read More → Medical Literature Monitoring
07/05/2023 No Comments
The medical literature is a vital source of information for monitoring the safety and benefit-risk profile of medicinal products. It is a significant source of ...
Read More → Responsible Person for EudraVigilance
06/28/2023 No Comments
Introduction EudraVigilance is a centralised European database of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European ...
Read More → Annual Summary Reports for Health Canada: Overview, Requirements, Format and Submission
06/27/2023 No Comments
What is an Annual Summary Report (ASR)? It is a comprehensive assessment of all known safety information for a marketed drug or natural health product. ...
Read More → Are ALT & AST Elevations Really Liver Function Tests
06/21/2023 No Comments
Liver biochemical tests are very commonly performed in clinical studies/clinical practice. These tests include: Alanine/aspartate aminotransferases (ALT/AST), Alkaline phosphatase (ALP), Gamma-glutamyl transferase (GGT) Bilirubin, Albumin ...
Read More → Serious Adverse Event Reconciliation in Clinical Studies
06/08/2023 No Comments
Serious Adverse Event Reconciliation in Clinical Studies WHAT IS SERIOUS ADVERSE EVENT (SAE) RECONCILIATION AND WHY IS IT REQUIRED The aim of Good Clinical Practice ...
Read More → Liver Injury with Cancer Chemotherapy
05/31/2023 No Comments
Liver Injury With Cancer Chemotherapy Cytotoxic chemotherapy is frequently associated with serum aminotransferaseelevations that are self-limited and that may subside with continued therapy.However, rare occurrences ...
Read More → Drug Induced Liver Injury in Premarketing Clinical Trials
04/19/2023 No Comments
Drug Induced Liver Injury in Premarketing Clinical Trials DILI (Drug Induced Liver Injury) is a rare but potentially fatal adverse drug reaction. DILI is a ...
Read More →